The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. (Q35017639)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

S Wu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

F Sun

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Y Zhang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Z Yang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Y Chen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

S Zhan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

16 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pharmacy and Therapeutics

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

7-13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127768%20AND%20SRC:MED&resulttype=core&format=json

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12102